ライフサイエンスコーパス: formoterol

1 terol, fluticasone-vilanterol, or mometasone-formoterol).

2 n of GRE-dependent transcription by the LABA formoterol.

3 ontrol measures generally favored budesonide/formoterol.

4 tiomers) of beta(2)AR agonists, albuterol or formoterol.

5 steroid or by whether the patient was taking formoterol.

6 S signature was augmented in the presence of formoterol.

7 ntraction is not alleviated by the B-agonist formoterol.

8 action is not alleviated by the beta-agonist formoterol.

9 following VML injury through treatment with formoterol.

10 gonists (LABAs) salmeterol, indacaterol, and formoterol.

11 milast N-oxide) each sensitized to the LABA, formoterol.

12 received placebo were switched to budesonide/formoterol.

13 oterol, dexamethasone, or dexamethasone plus formoterol.

14 ained beta(2) -adrenoceptor activation using Formoterol (10 mug kg(-1) day(-1) ), starting at the ons

15 rmoterol 400/12 mug twice daily + budesonide/formoterol 200/6 mug as needed for 12 weeks.

16 up consisted of two actuations of budesonide-formoterol (200 mug and 6 mug, respectively, per actuati

17 up consisted of two actuations of budesonide-formoterol (200 mug and 6 mug, respectively, per actuati

18 budesonide maintenance group); or budesonide-formoterol (200 mug of budesonide and 6 mug of formotero

19 randomly assigned inhaled placebo or inhaled formoterol 24 micrograms bid for 4 weeks each in a cross

20 y assigned (1:1) to either budesonide 50 mug-formoterol 3 mug, two actuations as needed, or salbutamo

21 2 of 621 who started) were randomly assigned formoterol 4.5 microg or terbutaline 0.5 mg as needed by

22 When taken as needed, formoterol 4.5 microg provided better asthma control tha

23 ith twice-daily ICS/LABA therapy (budesonide/formoterol 400 mug/12 mug; Turbuhaler).

24 eeks and maintenance therapy with budesonide/formoterol 400/12 mug twice daily + budesonide/formotero

25 gic receptors with salbutamol (40 microm) or formoterol (5 microm) resulted in significant enhancemen

26 lipid nanodiscs bound to the biased agonist formoterol(5), and the crystal structure of formoterol-b

27 eatment period by use of cumulative doses of formoterol (6-108 micrograms) with FEV1 and FEF25-75 mea

28 In human bronchial epithelial cells, formoterol, a long-acting B (2)-adrenoceptor agonist (LA

29 In human bronchial epithelial cells, formoterol, a long-acting beta (2)-adrenoceptor agonist

30 Our behavioral analyses revealed that formoterol, a long-acting beta2 adrenergic receptor agon

31 mportant, OPG-Fc combined with a low dose of formoterol, a member of a new generation of beta2-agonis

32 We recently showed that formoterol, a potent, highly specific, and long-acting b

33 y, these results contest the hypothesis that formoterol activates ERK1/2 in airway epithelia by nucle

34 Budesonide/formoterol administration led to a significant improveme

35 icate that the unique structural features of formoterol allow it to interact with the beta2AR to acti

36 Formoterol also inhibited the basal expression of early

37 rom 39 patients receiving mometasone furoate-formoterol and 36 events from 32 patients receiving mome

38 7 patients: 708 receiving mometasone furoate-formoterol and 779 receiving mometasone furoate.

39 Formoterol and albuterol were equally efficacious.

40 an bronchial epithelial cells (pHBECs) using formoterol and budesonide as representative LABA and ICS

41 curred in 0 and 4 patients in the budesonide/formoterol and budesonide groups, respectively.

42 Significantly, genes regulated by both formoterol and budesonide were over-represented in the g

43 act infection (5.8% and 4.4%) for budesonide/formoterol and budesonide, respectively.

44 While formoterol and clenbuterol increased cAMP, only formoter

45 to these differences in signaling, we docked formoterol and clenbuterol to six structures of the beta

46 s formoterol with fixed-dose budesonide plus formoterol and fixed-dose fluticasone plus salmeterol fo

47 s of patients with asthma, ICS combined with formoterol and ICS combined with SABA were each associat

48 lbuterol, and the long-acting beta2-agonists formoterol and olodaterol.

49 Recently, a direct interaction between formoterol and protein phosphatase 2A (PP2A) has been de

50 Formoterol and salbutamol also showed anti-inflammatory

51 The beta2 adrenoceptor agonists formoterol and salbutamol mediated suppression of IL-27p

52 nutes: mean difference at 60 minutes between formoterol and salmeterol in total airway resistance at

53 docyanopindolol-labeled bronchial membranes, formoterol and salmeterol induced high-affinity states o

54 The twice-daily beta2-agonists formoterol and salmeterol represent important advances.

55 Formoterol and salmeterol were highly selective for the

56 ught to identify the MB signaling pathway of formoterol and the differences in signaling between thes

57 The long-acting beta(2)-agonist formoterol and the glucocorticoid dexamethasone signific

58 We observe weakened interactions between formoterol and two serine residues in H5 at the orthoste

59 ximum and 6 h) after placebo with that after formoterol, and expressed this degree as a percentage of

60 The drugs salmeterol, formoterol, and salbutamol constitute the frontline trea

61 ee commonly used B2-AR agonists, salmeterol, formoterol, and salbutamol, using advanced simulation te

62 4 weeks' treatment with the beta2-AR agonist formoterol, and was not ablated by mTOR inhibition.

63 ctivation of the beta2AR increased invasion (formoterol area under the curve [AUC] relative to vehicl

64 rahydrocannabinol (THC) (dronabinol) and R,R-formoterol (arformoterol) illustrates how our strategy f

65 n FEV1 increased by 260 ml in the budesonide/formoterol arm compared with 5 ml in the placebo arm (P

66 e inhaler combination inhaled corticosteroid-formoterol as both maintenance and reliever (SMART) or i

67 ed to investigate the durations of action of formoterol at beta 1-adrenoceptors and of salmeterol at

68 Of interest, sustained administration of Formoterol at lower concentration (1 mug kg(-1) day(-1)

69 which was dependent on the cAMP/Ca(2+) loop (formoterol AUC in the presence of 2'5'-dideoxyadenosine

70 ly intraperitoneal injection with vehicle or formoterol beginning 24 hours after surgery and continui

71 o short-acting (salbutamol) and long-acting (formoterol) beta2 -agonists.

72 formoterol(5), and the crystal structure of formoterol-bound beta(1)AR coupled to the G-protein-mime

73 un-in period on low-dose ICS/LABA budesonide/formoterol (BUD/F) 200/6 one inhalation b.i.d.

74 e taken before and after 8 wk treatment with formoterol, budesonide, or placebo from atopic asthmatic

75 0 to February 2018, that compared budesonide-formoterol by SMART with maintenance inhaled corticoster

76 r to change control medication to budesonide/formoterol combination (BUD/FM) 320/9 mug/day or to keep

77 ng those receiving budesonide-glycopyrrolate-formoterol compared to fluticasone-umeclidinium-vilanter

78 he long duration of action of salmeterol and formoterol compared with salbutamol were attributed, at

79 y results occurred after chronic dosing with formoterol compared with salmeterol.

80 and efficacy of the long-acting beta-agonist formoterol compared with terbutaline, each taken as need

81 Thus, targeted kidney delivery of formoterol-containing nanoparticles is an improvement in

82 ly available and FDA-approved pharmaceutical formoterol could be a translational option to support mu

83 treatment of all epithelial cell models with formoterol decreased basal ERK1/2 phosphorylation.

84 d the duration of gene expression induced by formoterol, dexamethasone, or dexamethasone plus formote

85 he proportion of patients reducing their ICS-formoterol dose by week 32.

86 verall, 110 (92%) patients reduced their ICS-formoterol dose: 18 (15%) to medium-dose, 20 (17%) to lo

87 Twenty-five patients received budesonide/formoterol during the study.

88 Formoterol enhanced injured muscle mass, while mitigatin

89 Treatment with formoterol enhanced mass of the injured muscle and whole

90 adenylyl cyclase, namely epinephrine > or = formoterol = fenoterol > terbutaline = zinterol = albute

91 ctivity of other beta2-agonists (salbutamol, formoterol, fenoterol, clenbuterol, or adrenaline).

92 nd combination ICS-LABA inhalers (budesonide-formoterol, fluticasone-salmeterol, fluticasone-vilanter

93 ated combination therapy with budesonide and formoterol for both maintenance and relief of symptoms.

94 Finally, compared to treatment with formoterol-free drug alone, these nanoparticles did not

95 ved beclometasone dipropionate (100 mug) and formoterol fumarate (6 mug) in two actuations twice dail

96 compared with beclometasone dipropionate and formoterol fumarate (BDP/FF) treatment.

97 late/formoterol fumarate (GFF) or budesonide/formoterol fumarate (BFF).

98 riple therapy with budesonide/glycopyrrolate/formoterol fumarate (BGF) reduced rates of moderate/seve

99 dipropionate (BDP), long-acting B(2)-agonist formoterol fumarate (FF), and long-acting muscarinic ant

100 dipropionate (BDP; inhaled corticosteroid), formoterol fumarate (FF; long-acting beta(2) agonist), a

101 mpared with dual therapy with glycopyrrolate/formoterol fumarate (GFF) or budesonide/formoterol fumar

102 fficacy and safety of Fluticasone propionate/formoterol fumarate hydrate (FP/FM) was evaluated in ped

103 eliever (SMART) regimen (with budesonide and formoterol fumarate), and anti-IgE therapy.

104 t with extrafine beclometasone dipropionate, formoterol fumarate, and glycopyrronium bromide (BDP/FF/

105 e formulation of beclometasone dipropionate, formoterol fumarate, and glycopyrronium bromide (BDP/FF/

106 nflammatory reliever therapy with budesonide-formoterol, given on an as-needed basis, is superior to

107 Combination LAMA-LABA inhalers (aclidinium-formoterol, glycopyrronium-formoterol, glycopyrronium-in

108 alers (aclidinium-formoterol, glycopyrronium-formoterol, glycopyrronium-indacaterol, tiotropium-oloda

109 dose (MD) or high-dose (HD) of beclometasone/formoterol/glycopyrronium bromide (BDP/FOR/GLY) compared

110 dverse event was 162 (91%) in the budesonide-formoterol group and 167 (92%) in the salbutamol group (

111 ts to treatment (179 [50%] to the budesonide-formoterol group and 181 [50%] to the salbutamol group).

112 was 107+/-109 mug per day in the budesonide-formoterol group and 222+/-113 mug per day in the budeso

113 re exacerbations was lower in the budesonide-formoterol group than in both the albuterol group (9 vs.

114 f asthma attacks was lower in the budesonide-formoterol group than in the salbutamol group-cluster-ad

115 roup (absolute rate, 0.195 in the budesonide-formoterol group vs. 0.175 in the budesonide maintenance

116 nualized exacerbation rate in the budesonide-formoterol group was lower than that in the albuterol gr

117 through a Turbuhaler as needed) (budesonide-formoterol group).

118 ients who received budesonide-glycopyrrolate-formoterol had a 9% higher incidence of first moderate o

119 Patients taking formoterol had a longer time to their first severe asthm

120 ric binding site of beta(1)AR, and find that formoterol has a lower affinity for the beta(1)AR-betaar

121 The beta(2) adrenergic receptor agonist formoterol has shown promise in other severe injury mode

122 Unfortunately, systemic administration of formoterol has the potential for adverse cardiovascular

123 eatment with beta(2) receptor agonists (e.g. formoterol) improves metabolic and skeletal muscle funct

124 irway epithelia, roflumilast interacted with formoterol in a positive cooperative manner to enhance t

125 than eight actuations per day of budesonide-formoterol in addition to the four maintenance doses in

126 Formoterol in combination with an ICS in a single inhale

127 We sought to determine whether administering formoterol in combination with mometasone furoate increa

128 e potencies and efficacies of salmeterol and formoterol in humans.

129 Early treatment with inhaled budesonide/formoterol in patients at risk for acute respiratory dis

130 erol compared with budesonide-glycopyrrolate-formoterol in people with COPD.

131 calabrutinib synergized with epinephrine and formoterol in preventing mortality at 5 minutes after ch

132 l, two indacaterol analogues, salmeterol and formoterol) in monounsaturated model membranes using mag

133 Only formoterol increased cGMP.

134 moterol and clenbuterol increased cAMP, only formoterol increased the phosphorylation of Akt and its

135 me distributions for each state reveals that formoterol increases the frequency of activation transit

136 ive of evaluating whether mometasone furoate-formoterol increases the risk of SAOs (adjudicated hospi

137 ted in the genome; moreover, budesonide plus formoterol induced and repressed 609 and 577 mRNAs, resp

138 Formoterol induced MB as measured by increases in uncoup

139 Although repression of formoterol-induced proinflammatory mRNAs should be benef

140 entially beneficial) effect of budesonide on formoterol-induced transcripts, including those encoding

141 beta-2 adrenergic receptor (beta2AR) agonist formoterol induces mitochondrial biogenesis (MB), but ot

142 fficacy and safety of combination budesonide/formoterol inhaler according to a single inhaler regimen

143 The Single combination budesonide-formoterol inhaler Maintenance And Reliever Therapy (SMA

144 d to clenbuterol, the methoxyphenyl group of formoterol interacted more frequently with V114 and F193

145 The beta(2) adrenergic receptor agonist, formoterol, is an inducer of mitochondrial biogenesis an

146 ng combined inhaler of budesonide (ICS) with formoterol (LABA) was effective to reduce these symptoms

147 In this cell line, formoterol, like the nonselective beta-adrenoceptor agon

148 After a 4-week run-in on beclomethasone/formoterol maintenance and reliever therapy (baseline),

149 Beclomethasone/formoterol maintenance and reliever therapy requirement

150 data set from 3 studies comparing budesonide/formoterol maintenance and reliever therapy with fixed-d

151 cs were randomly assigned to budesonide plus formoterol maintenance and reliever therapy, fixed-dose

152 the VHA formulary transition from budesonide-formoterol metered-dose inhaler to fluticasone-salmetero

153 Treatment with budesonide-formoterol metered-dose inhaler vs fluticasone-salmetero

154 e, 260 268 patients switched from budesonide-formoterol metered-dose therapy to fluticasone-salmetero

155 Among 11,729 patients (mometasone furoate-formoterol, n = 5,868; mometasone furoate, n = 5,861), a

156 The effect of budesonide/formoterol on the FEV1 was maintained in the 13 patients

157 rmoterol (200 mug of budesonide and 6 mug of formoterol, one inhalation through a Turbuhaler as neede

158 New initiators of budesonide-glycopyrrolate-formoterol or fluticasone-umeclidinium-vilanterol betwee

159 s with mild/severe BOS to receive budesonide/formoterol or placebo for 6 months.

160 ositive effects on cognition in Ts65Dn mice, formoterol or similar beta2 adrenergic receptor agonists

161 th salmeterol (OR, 1.7 [CI, 1.1 to 2.7]) and formoterol (OR, 3.2 [CI, 1.7 to 6.0]) and in children (O

162 reliever therapy, fixed-dose budesonide plus formoterol, or fixed-dose fluticasone plus salmeterol fo

163 D while receiving treatment with salmeterol, formoterol, or salbutamol.

164 r FEF(25-75), were significantly better with formoterol over the entire 60 minutes: mean difference a

165 6 +/- 0.32), increased intracellular Ca(2+) (formoterol pEC50 8.20 +/- 0.33) and reduced phosphorylat

166 beta2AR activation results in elevated cAMP (formoterol pEC50 9.86 +/- 0.32), increased intracellular

167 0.33) and reduced phosphorylated ERK (pERK; formoterol pIC50 11.62 +/- 0.31).

168 ized 1:1 to 320/9 mug twice-daily budesonide/formoterol pMDI or 320 mug twice-daily budesonide pMDI.

169 In this population budesonide/formoterol pMDI was well tolerated over 12 months, with

170 safety and asthma control with a budesonide/formoterol pressurized metered-dose inhaler (pMDI) versu

171 In BEAS-2B cells, formoterol produced 267 (212 induced; 55 repressed) gene

172 In BEAS-2B cells, formoterol produced 267 (212 induced; 55 repressed) gene

173 that B (2)-adrenoceptor agonists, including formoterol, promote biased, B-arrestin (Arr) 2-dependent

174 drenoceptor agonist biased toward BArr2, nor formoterol promoted ERK1/2 phosphorylation in BEAS-2B ce

175 Compared with SABA alone, ICS-formoterol (RD, -0.6% [95% CI, -1.3% to 0%]) was not ass

176 Therefore, it seemed that formoterol relied on its moderately lipophilic nature to

177 aged 5-15 years with mild asthma, budesonide-formoterol reliever monotherapy is superior to salbutamo

178 Combination inhaled corticosteroid-formoterol reliever monotherapy reduces the rate of asth

179 h duration of action, whereas salmeterol and formoterol require twice-daily administration.

180 Treatment with formoterol restored renal function, rescued renal tubule

181 s unique to beta 2-adrenoceptors or, as with formoterol, resulted from its lipophilic nature and part

182 ociated with fewer severe exacerbations (ICS-formoterol risk ratio [RR], 0.65 [95% CI, 0.60-0.72]; ri

183 associated with improved asthma control (ICS-formoterol RR improvement [MID] in total score, 1.07 [95

184 Formoterol's access is through the aqueous path shared b

185 igands show that binding of the full agonist formoterol shifts the conformational distribution in fav

186 mug of small-particle hydrofluoroalkane 134a-formoterol solution or 50 mug of large-particle salmeter

187 Concomitantly, formoterol stimulated mitochondrial biogenesis and resto

188 ell surface B2ARs internalize in response to formoterol-stimulation in ES progenitor cells but not fo

189 montelukast (Singulair), and (4) budesonide/formoterol (Symbicort).

190 ompatible polymeric nanoparticles containing formoterol that target the kidney, thereby decreasing th

191 oup) or continue (reference group) their ICS-formoterol therapy for 32 weeks, followed by a 16-week m

192 nanoparticles is an improvement in standard formoterol therapy for ischemia-reperfusion-induced acut

193 iduals whose asthma is not controlled by ICS-formoterol therapy for step 5 (moderate-severe persisten

194 te persistent asthma in step 3 (low-dose ICS-formoterol therapy) and step 4 (medium-dose ICS-formoter

195 moterol therapy) and step 4 (medium-dose ICS-formoterol therapy) for both daily and as-needed therapy

196 Conversely, the ability of formoterol to enhance both gene induction and repression

197 suggest that the ability of roflumilast and formoterol to interact in this way supports the concept

198 The addition of formoterol to mometasone furoate maintenance therapy did

199 d to unrestricted or restricted activity and formoterol treatment or no treatment; age-matched injury

200 After formoterol treatment there was a significant decrease in

201 idation, although changes were attenuated by formoterol treatment.

202 Salmeterol and formoterol, two new long-acting beta 2-agonists were equ

203 nvolving adults with mild asthma, budesonide-formoterol used as needed was superior to albuterol used

204 blind, placebo-controlled trials, budesonide-formoterol used on an as-needed basis resulted in a lowe

205 t-treatment year) were lower with budesonide/formoterol versus budesonide (incidence, 7.7% vs 14.0% [

206 rbation was longer (P= .018) with budesonide/formoterol versus budesonide.

207 sthma exacerbation in the mometasone furoate-formoterol versus mometasone furoate group was 0.89 (95%

208 for the first SAO in the mometasone furoate-formoterol versus mometasone furoate group was 1.22 (95%

209 Aerosolized budesonide/formoterol versus placebo bid for up to 5 days.

210 were significantly greater improvements with formoterol versus salmeterol in all IOS outcomes and FEF

211 serious asthma-related event with budesonide-formoterol vs budesonide was 1.29 (95% CI, 0.63-2.65) co

212 eriments, cAMP responses to isoprenaline and formoterol waned with increasing numbers of washing proc

213 Postmortem analyses revealed that the use of formoterol was associated with a significant improvement

214 In an indirect comparison with ICS-SABA, ICS-formoterol was associated with fewer severe exacerbation

215 response element-dependent transcription by formoterol was displaced to the left by PDE4, but not PD

216 Formoterol was more efficacious (86 +/- 5%) than salmete

217 Budesonide-glycopyrrolate-formoterol was not associated with improved clinical out

218 h induction of many mRNAs by budesonide plus formoterol was supra-additive, the dominant (and potenti

219 nd high doses of budesonide with and without formoterol were compared in patients with asthma.

220 red an adjustable regimen of budesonide plus formoterol with fixed-dose budesonide plus formoterol an